Erini R. Svokos

Ms. Svokos’s transactional experience includes the following strategic alliance and collaboration transactions and mergers and acquisitions:

Strategic Alliances and Collaborations

• insitro in its strategic collaboration with Gilead to discover and develop therapies for patients with NASH, with up to $50 million in near-term payments, plus royalties and milestones
• Obsidian Therapeutics in its strategic collaboration with Celgene to develop novel, regulated cell therapies using Obsidian’s destabilizing domain technology
• Moderna Therapeutics in its strategic collaboration with Merck to advance novel mRNA-based personalized cancer vaccines, with an upfront payment of $200 million, and the expansion of the strategic alliance to include additional shared antigen mRNA cancer vaccines, with an equity investment of $125 million
• ImmuNext in its exclusive, worldwide licensing agreement with Sanofi to develop and commercialize a CD40L monoclonal antibody to treat autoimmune diseases, with potential deal value of up to $500 million, plus royalties
• Teva Pharmaceuticals in its license agreement with Heptares to develop and commercialize novel, small-molecule calcitonin gene-related peptide antagonists discovered by Heptares, valued up to $410 million, plus royalties
• BlueRock Therapeutics, a next-generation regenerative medicine company, in its $225 million financing by Bayer and Versant Ventures and seminal in-licenses and alliances with Memorial Sloan Kettering, the Centre for Commercialization of Regenerative Medicine and University Health Networks
• Blueprint Medicines in its worldwide collaboration with Roche, valued up to $1 billion with a $45 million upfront payment.
• Surface Oncology in its collaboration with Novartis to develop next generation immunotherapies, with Surface eligible to receive up to $170 million in near term cash, plus milestones and royalties
• Teva Pharmaceuticals, in its worldwide collaboration with Regeneron Pharmaceuticals to develop and commercialize fasinumab, with an upfront payment of $250 million, as well as ongoing research and development costs of approximately $1 billion

M&A

• Syntimmune in its sale to Alexion, valued up to $1.2 billion, with an up-front payment of $400 million
• Nimbus Therapeutics in the negotiation of a strategic alliance with Celgene Corporation in immunology
• Delinia Therapeutics in its sale to Celgene, valued up to $775 million with an up-front payment of $300 million
• Nimbus Therapeutics in connection with the $1.2 billion sale of its ACC inhibitor program to Gilead Biosciences
• Promedior in its exclusive purchase option agreement with Bristol-Myers Squibb with potential deal value up to $1.25 billion